title: Adaptive Immune Responses and HER2/neu Positive Breast Cancer.
abstract: Oncogenic signaling, such as HER2/neu signaling, has been shown to play major role for tumorigenesis in a subset of breast cancer patients. The use of anti-HER2/neu antibody has not only revealed the mechanisms for HER2/neu signaling but also shown a therapeutic advantage of its blockade. Indeed, the use of trastuzumab has greatly improved the treatment of HER2-positive breast cancer. Although this therapy has been used in the clinic for over twenty years, recent data is still uncovering new mechanisms by which this antibody exerts its anti-tumor activity. In addition to an improved understanding of the molecular mechanisms by which this therapy inhibits growth of tumor cells, the discovery that anti-HE2/neu therapy initiates and requires the adaptive immune system is one of these new mechanisms. The presence of anti-HER2/neu initiated adaptive immunity gives credence to efforts targeted at stimulating the immune system in treating HER2 positive breast cancer. This review focuses on the role of the inflammatory response in HER2 positive breast cancer with particular emphasis on trastuzumab therapy.
authors: Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637, USA.
authors: Eric D
authors: ED
authors: Mortenson
authors: Yang-Xin
authors: YX
authors: Fu
keywords: Adaptive immunity; Antibody drug conjugates; Antibody therapies; Breast cancer; Combination therapies; HER2/neu; Herceptin; Immune responses; Immunotherapy; Inflammation; Innate immunity; Oncogenic signaling; Pathobiology; Trastuzumab